Table 3.
Immune checkpoint inhibitors in combination with tyrosine kinase inhibitors in hepatocellular carcinoma
| Phase | Target | Agent | Company | Trial # |
|---|---|---|---|---|
| 1–2 | PD-1 + TGF-β receptor I | Nivolumab + galunisertib (LY2157299) | Eli Lilly | NCT02423343 |
| 1 | PD-L1 + VEGFR-2 | Ramucirumab + durvalumab (MEDI4736) | Eli Lilly | NCT02572687 |
| 1 | PD-1 + multikinase | Pembrolizumab + lenvatinib | Eisai | NCT03006926 |
| 1 | PD-1 + multikinase | Pembrolizumab + nintedanib | Gustave Roussy | NCT02856425 |
| 1 | PD-1 + multikinase | PDR001 + sorafenib | Novartis | NCT02988440 |
| 1–2 | PD-1 + c-Met | PDR001 + capmatinib (INC280) | Novartis | NCT02795429 |
| 1–2 | PD-1 + CTLA-4 + MET/VEGFR2 | Nivolumab + ipilimumab + cabozantinib | BMS | NCT01658878 |
| 1 | PD-1 + multikinase | Nivolumab + lenvatinib | Ono | |
| 1–2 | PD-L1 + multikinase | Avelumab + axitinib | Pfizer | NCT03289533 |
| 1–2 | PD-L1 + multikinase | Atezolizumab + bevacizumab | Roche |